hold on there's just too much going on in Congress lmao...
Requires federal agencies to disclose drug pricing agreements.
Sen. Wyden introduced this bill, supported by many other senators.
Introduced in Senate, in committee, no vote yet.
This bill requires the Department of Health and Human Services to publicly release all documents and communications related to specific drug pricing agreements between federal agencies and pharmaceutical manufacturers entered into after January 20, 2025. Senator Wyden introduced the bill, and it was referred to the Senate Committee on Health, Education, Labor, and Pensions, where it awaits further consideration.
Introduced Apr 21, 2026
This bill was introduced in the Senate on April 21, 2026, and then referred to the Senate Committee on Health, Education, Labor, and Pensions. For it to become law, it must pass through this committee, be voted on and passed by the full Senate, then pass the House of Representatives, and finally be signed by the President.
If this bill passes, the public would gain access to details about how drug manufacturers negotiate prices with the U.S. government, including deals affecting 'most favored nation' pricing or direct-to-consumer sales. This transparency could shed light on whether certain agreements influence what you pay for prescription drugs. Additionally, federal agencies like the Congressional Budget Office will report on the economic effects of these agreements, including impacts on individual cost savings and government health programs.
Supporters Say
Supporters believe this bill will bring transparency to government drug pricing agreements.
Critics Say
Some might argue that broad disclosures could compromise sensitive proprietary information, despite allowed redactions.
The bill's proponents likely emphasize the need for transparency in agreements that can significantly impact healthcare costs and public spending. However, the bill itself acknowledges that some proprietary pricing information, or data legally protected by foreign laws or court orders, may need to be withheld or redacted, suggesting potential concerns about protecting sensitive business details that critics might raise.